Lexeo Therapeutics, Inc. 8-K

What Happened
Lexeo Therapeutics, Inc. filed an 8-K on February 5, 2026 disclosing that on January 30, 2026 it entered a Transition and Consulting Agreement with Dr. Adler, effective February 1, 2026. Dr. Adler stepped down from his role as Head of Research and will provide advisory services during a Transition Period that runs until the earlier of July 31, 2026 or termination of the agreement.

Key Details

• Transition Period effective Feb 1, 2026 and ends no later than July 31, 2026 (unless earlier terminated).
• Dr. Adler will be paid up to $62,500 total, paid in monthly installments during the Transition Period.
• Service-vesting equity awards will continue to vest during the Transition Period.
• Dr. Adler’s post-termination option exercise window is extended to six months after the end of the Transition Period.
• He may receive an additional $1,000 lump-sum if he signs a supplemental release after the Transition Period.
• Agreement contains customary release of claims, non-disparagement, and cooperation provisions.

Why It Matters
This is an executive change that preserves continuity: Lexeo retains Dr. Adler’s advisory support and continues vesting of his service-based equity, which may help preserve institutional research knowledge. The cash commitment is modest (up to $62,500) and the extended option exercise period affects the timing for any option exercises but is unlikely to materially change dilution. Investors should note this as a governance/leadership update under Item 5.02; the filing does not disclose a replacement or material changes to company financial guidance.